The peptide conversation is shifting. Secretary RFK Jr. recently announced that the FDA plans to move 14 peptides from Category 2 back to Category 1 restoring FDA recognized status and making them BPC 157 FDA Approval Status 2026: RFK Jr, Advisory Committee & Reclassification FDA's Bulks List: Section 503A KLOW Blend 80mg Koi Peptides Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg #